ArticleMolecules (Basel, Switzerland)2026
Design, Synthesis,
Mesut Işık, Abdüllatif Karakaya, Ulviye Acar Çevik, Adem Necip, Hatice Esra Duran, Bilge Çiftçi, Yusuf Özkay, Zafer Asım Kaplancıklı, Şükrü Beydemir
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Mesut IşıkDepartment of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0002-4677-8104 Abdüllatif KarakayaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, 67600 Zonguldak, Turkey.ORCID 0009-0003-9619-6705 Ulviye Acar ÇevikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey.ORCID 0000-0003-1879-1034 Adem NecipDepartment of Pharmacy Services, Vocational School of Health Services, Harran University, 63300 Şanlıurfa, Turkey.ORCID 0000-0002-2092-7829 Hatice Esra DuranDepartment of Medical Biochemistry, Faculty of Medicine, Kafkas University, 36100 Kars, Turkey.ORCID 0000-0003-2080-0091 Bilge ÇiftçiVocational School of Health Services, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0002-4153-1209 Yusuf ÖzkayDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey.ORCID 0000-0001-5948-1855 Zafer Asım KaplancıklıDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey.ORCID 0000-0003-2252-0923 Şükrü BeydemirDepartment of Biochemistry, Faculty of Pharmacy, Anadolu Universty, 26470 Eskisehir, Turkey.ORCID 0000-0003-3667-6902 Funding
Anadolu University THD-2026-3503
6 · The paper itselfAbstract
In this study, due to the side effect profiles and low efficacy of currently used inhibitors, novel benzimidazole-oxadiazole derivatives (
Indexed as
Aldehyde Reductasealpha-GlucosidasesBenzimidazolesDrug DesignGlycoside Hydrolase InhibitorsHypoglycemic AgentsMolecular Docking SimulationOxadiazolesHumansMolecular StructureStructure-Activity RelationshipAldehyde Reductasealpha-GlucosidasesbenzimidazoleBenzimidazolesGlycoside Hydrolase InhibitorsHypoglycemic AgentsOxadiazolesaldose reductasebenzimidazolemolecular dockingoxadiazoleα-glucosidase
Identifiers
PMID42588484
PMCPMC13468218
What Socratic holds
Textmetadata
Read underepoch 390